

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|---------------|-------------------------|-------------------------|------------------|
| 09/831,954 | 06/25/2001 | Hubert Jan Jozef Loozen | O/98414-US | 9900 |
| 759 | 90 12/10/2002 | | | |
| William M Blackstone Akzo Nobel 1300 Piccard Drive Suite 206 Rockville, MD 20850-4373 | | | EXAMINER | |
| | | | JIANG, SHAOJIA A | |
| | | | ART UNIT | PAPER NUMBER |
| | | | 1617 | |
| | | | DATE MAILED: 12/10/2002 | |

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. Applicant(s) 09/831,954 LOOZEN ET AL. Advisory Action Examiner Art Unit Shaojia A. Jiang 1617 --The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 27 November 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. PERIOD FOR REPLY [check either a) or b)] a) The period for reply expires <u>3</u> months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 1. A Notice of Appeal was filed on _____. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal. 2. The proposed amendment(s) will not be entered because: (a) Ithey raise new issues that would require further consideration and/or search (see NOTE below); (b) they raise the issue of new matter (see Note below); (c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) they present additional claims without canceling a corresponding number of finally rejected claims. NOTE: See attachment. 3. Applicant's reply has overcome the following rejection(s): _____. 4. Newly proposed or amended claim(s) ____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: See attachment. 6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection. 7. \boxtimes For purposes of Appeal, the proposed amendment(s) a) \boxtimes will not be entered or b) \square will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: none. Claim(s) objected to: none. Claim(s) rejected: 1-5 and 7.

9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s). 10. Other: ____

8. The proposed drawing correction filed on ____ is a) approved or b) disapproved by the Examiner.

SREENI PADMANABHAN

Claim(s) withdrawn from consideration: none.

Application/Control Number: 09/831,954

Art Unit: 1617

Advisory Action

This Office Action is a response to Applicant's amendment and response <u>after</u>

FINAL filed on November 27, 2002.

- 2. Applicant's proposed amended claims changing to "a pharmaceutical composition" from "a steroid compound" and adding a new method claim, present a new issue for search and consideration by the Examiner.
- 5. Applicant's remarks filed November 27, 2002 with respect to the rejection of claims 1-5 and 7 made under 35 U.S.C. 103(a) as being unpatentable over Lobaccaro et al. and the rejection of claims 1-5 and 7 made under 35 U.S.C. 103(a) as being unpatentable over Napolitano et al. have been fully considered but are unpersuasive for reasons of record stated in the Final Office Action dated August 27, 2002.

Applicant's remarks regarding the unexpected results herein have been considered but not found persuasive. As discussed in the Final Rejection, Applicant's results shown in Table A of the specification at pages 14 herein provides no clear and convincing evidence of nonobviousness or unexpected results over the cited prior art since Table A provides no clear data in support of the conclusion that these compounds are agonist or antagonist to ER- α or EP- β . Thus, the results in Table A is considered insufficient to establish any unexpected results.

As discussed in the Final Rejection, the claimed invention is clearly obvious in view of the prior art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Jiang, whose telephone number is (703) 305-1008. The examiner can normally be reached on Monday-Friday from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, Ph.D., can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-1235.

Shaojia A. Jiang, Ph.D. Patent Examiner, AU 1617 December 6, 2002

> SREENI PADMANABHAN PRIMARY EXAMINER

> > 12/8/2